LABEL Opioids Act

Bill: 117-hr-1026
Sponsor: full_name: Rep. Stanton, Greg [D-AZ-9]
Introduced: 2021-02-11
Policy area: Crime and Law Enforcement
Subjects: Administrative law and regulatory procedures

Consumer affairs

Criminal justice information and records

Department of Health and Human Services

Drug safety, medical device, and laboratory regulation

Drug trafficking and controlled substances

Drug, alcohol, tobacco use

Health information and medical records

Prescription drugs
Latest action: action_date: 2021-04-28
text: Referred to the Subcommittee on Crime, Terrorism, and Homeland Security.

Summaries:
action_date: 2021-02-11
action_desc: Introduced in House
text: <p><strong>Lessening Addiction By Enhancing Labeling Opioids Act of 2021 or the LABEL Opioids Act</strong></p> <p>This bill requires prescription opioids to contain a warning label specifying that the opioids may cause dependence, addiction, and overdose. A registrant (e.g., a pharmacist) who dispenses an opioid in violation of the labeling requirement is subject to penalties.</p>

tv_txt: I 117th CONGRESS 1st Session H. R. 1026 IN THE HOUSE OF REPRESENTATIVES February 11, 2021 Mr. Stanton introduced the following bill; which was referred to the Committee on Energy and Commerce , and in addition to the Committee on the Judiciary , for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned A BILL To amend the Controlled Substances Act to require dispensers of certain opioids and opiates to affix on the container or package thereof a clear, concise warning that the opioid or opiate can cause dependence, addiction, and overdose, and for other purposes.

1. Short title This Act may be cited as the Lessening Addiction By Enhancing Labeling Opioids Act of 2021 or the LABEL Opioids Act . 2. Lessening addiction by enhancing labeling of opioids (a) In general Section 305(c) of the Controlled Substances Act ( 21 U.S.C. 825(c) ) is amended by striking which shall provide that the label and all that follows through the period and inserting the following: which shall provide that— (1) the label of a drug listed in schedule II, III, or IV shall, when dispensed to or for a patient, contain a clear, concise warning that it is a crime to transfer the drug to any person other than the patient; and (2) the label of any container or package containing an opioid or opiate listed in schedule II, III, IV, or V (other than a drug that is approved or authorized by the Food and Drug Administration for the treatment of addiction or an opioid use disorder) shall, when dispensed to or for a patient, contain a clear, concise warning that the opioids or opiates dispensed can cause dependence, addiction, and overdose. ; (b) Prohibited act Section 402(a)(3) of the Controlled Substances Act ( 21 U.S.C. 842(a)(3) ) is amended after distribute by inserting or dispense . (c) Regulations (1) Regulations Not later than 1 year after the date of enactment of this Act, the Secretary of Health and Human Services shall prescribe final regulations to implement the amendments made by subsections (a) and (b), which regulations shall be effective beginning on the date that is 2 years after the date of enactment of this Act. (2) Interim rules The Secretary of Health and Human Services may issue the regulations required under paragraph (1) by interim rule to the extent necessary to comply with the timing requirement in paragraph (1). (d) Applicability The amendment made by subsection (b) applies beginning on the date that is 2 years after the date of enactment of this Act.